NO20054440L - Flytende formuleringer av tumornekrosefaktorbindende proteiner - Google Patents

Flytende formuleringer av tumornekrosefaktorbindende proteiner

Info

Publication number: NO20054440L
Authority: NO; Norway
Prior art keywords: binding proteins; necrosis factor; tumor necrosis; liquid formulations; factor binding
Prior art date: 2003-02-28

Application number

NO20054440A

Other languages

English (en)

Norwegian (no)

Inventor

Fabrizio Samaritani

Alessandra Del Rio

Rita Agostinetto

Original Assignee

Ares Trading Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-28

Filing date

2005-09-26

Publication date

2005-09-26

2005-09-26 Application filed by Ares Trading Sa filed Critical Ares Trading Sa

2005-09-26 Publication of NO20054440L publication Critical patent/NO20054440L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Cell Biology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

NO20054440A 2003-02-28 2005-09-26 Flytende formuleringer av tumornekrosefaktorbindende proteiner NO20054440L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03100505		2003-02-28
PCT/EP2004/050118 WO2004075918A1 (en)	2003-02-28	2004-02-11	Liquid formulations of tumor necrosis factor-binding proteins

Publications (1)

Publication Number	Publication Date
NO20054440L true NO20054440L (no)	2005-09-26

Family

ID=32921619

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054440A NO20054440L (no)	2003-02-28	2005-09-26	Flytende formuleringer av tumornekrosefaktorbindende proteiner

Country Status (22)

Country	Link
US (3)	US8937045B2 (ja)
EP (1)	EP1603596B1 (ja)
JP (1)	JP4980048B2 (ja)
KR (1)	KR20050105486A (ja)
CN (1)	CN100563712C (ja)
AR (1)	AR043418A1 (ja)
AT (1)	ATE394123T1 (ja)
BR (1)	BRPI0407649A (ja)
CA (1)	CA2515539A1 (ja)
DE (1)	DE602004013557D1 (ja)
EA (1)	EA009079B1 (ja)
ES (1)	ES2304602T3 (ja)
HK (1)	HK1085677A1 (ja)
HR (1)	HRP20050706A2 (ja)
IL (1)	IL170414A (ja)
MX (1)	MXPA05009135A (ja)
NO (1)	NO20054440L (ja)
PL (1)	PL213501B1 (ja)
RS (1)	RS51041B (ja)
UA (1)	UA82503C2 (ja)
WO (1)	WO2004075918A1 (ja)
ZA (1)	ZA200506504B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040033228A1 (en)	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
NZ602498A (en) *	2007-11-30	2014-08-29	Abbvie Inc	Protein formulations and methods of making same
SG175188A1 (en) *	2009-05-04	2011-11-28	Abbott Biotech Ltd	Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
PL2637690T3 (pl)	2010-11-11	2017-03-31	Abbvie Biotechnology Ltd	Płynne formulacje zawierające przeciwciało anty-tnf alfa o wysokim stężeniu
WO2013006454A1 (en)	2011-07-01	2013-01-10	Biogen Idec Ma Inc.	Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use
TWI595883B (zh)	2011-10-18	2017-08-21	柯赫勒斯生物科學有限公司	用木糖醇穩定化之依那西普調配物
US10493151B2 (en)	2011-10-18	2019-12-03	Coherus Biosciences, Inc.	Etanercept formulations stabilized with sodium chloride
JP6120452B2 (ja)	2011-10-31	2017-04-26	ジェネンテック，インコーポレイテッド	抗体製剤
BR112015000203A2 (pt)	2012-07-09	2017-06-27	Coherus Biosciences Inc	formulações de etanercept que exibem redução marcada em partículas sub-visíveis
MX360044B (es)	2012-09-11	2018-10-19	Coherus Biosciences Inc	Etanercept plegado correctamente con alta pureza y un rendimiento excelente.
JP6431844B2 (ja)	2012-10-26	2018-11-28	ルピンアトランティスホールディングスエスエーＬｕｐｉｎＡｔｌａｎｔｉｓＨｏｌｄｉｎｇｓＳａ	Ｔｎｆｒ：ｆｃ融合プロテインの安定な医薬組成物
JP5684954B1 (ja)	2014-06-26	2015-03-18	丸石製薬株式会社	安定性を改善したロクロニウム製剤
RU2724900C1 (ru) *	2019-10-24	2020-06-26	Маруиси Фармасьютикал Ко., Лтд.	Препарат рокурония с улучшенной стабильностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6552170B1 (en) *	1990-04-06	2003-04-22	Amgen Inc.	PEGylation reagents and compounds formed therewith
NZ256293A (en)	1992-09-15	1997-06-24	Immunex Corp	Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
CA2139385C (en) *	1994-02-04	2001-12-25	Gottfried Alber	Products containing g-csf and tnf binding protein
EP0839046B1 (en) *	1995-07-14	2002-01-23	Applied Research Systems ARS Holding N.V.	Tnf receptor and steroid hormone dhea in a combined therapy
MA24169A1 (fr) *	1996-05-08	1997-12-31	Hoffmann La Roche	Traitement de l'asthme a l'aide de la tnfr-ig
DK0942740T3 (da) *	1996-12-06	2003-12-15	Amgen Inc	Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
US7087224B2 (en) *	2000-10-31	2006-08-08	Amgen Inc.	Method of treating anemia by administering IL-1ra
US6818613B2 (en) *	2001-11-07	2004-11-16	Ortho-Mcneil Pharmaceutical, Inc.	Aqueous sustained-release formulations of proteins
US20030180287A1 (en) *	2002-02-27	2003-09-25	Immunex Corporation	Polypeptide formulation

2004
- 2004-02-11 BR BRPI0407649-4A patent/BRPI0407649A/pt not_active IP Right Cessation
- 2004-02-11 MX MXPA05009135A patent/MXPA05009135A/es active IP Right Grant
- 2004-02-11 RS YUP-2005/0662A patent/RS51041B/sr unknown
- 2004-02-11 DE DE602004013557T patent/DE602004013557D1/de not_active Expired - Lifetime
- 2004-02-11 EA EA200501230A patent/EA009079B1/ru not_active IP Right Cessation
- 2004-02-11 EP EP04710041A patent/EP1603596B1/en not_active Expired - Lifetime
- 2004-02-11 KR KR1020057015762A patent/KR20050105486A/ko not_active Application Discontinuation
- 2004-02-11 WO PCT/EP2004/050118 patent/WO2004075918A1/en active IP Right Grant
- 2004-02-11 JP JP2006502021A patent/JP4980048B2/ja not_active Expired - Fee Related
- 2004-02-11 US US10/547,307 patent/US8937045B2/en not_active Expired - Fee Related
- 2004-02-11 CN CNB2004800103089A patent/CN100563712C/zh not_active Expired - Lifetime
- 2004-02-11 CA CA002515539A patent/CA2515539A1/en not_active Abandoned
- 2004-02-11 AT AT04710041T patent/ATE394123T1/de not_active IP Right Cessation
- 2004-02-11 ES ES04710041T patent/ES2304602T3/es not_active Expired - Lifetime
- 2004-02-11 PL PL378290A patent/PL213501B1/pl unknown
- 2004-02-27 AR ARP040100618A patent/AR043418A1/es not_active Application Discontinuation
- 2004-11-02 UA UAA200508323A patent/UA82503C2/uk unknown
2005
- 2005-08-09 HR HR20050706A patent/HRP20050706A2/hr not_active Application Discontinuation
- 2005-08-15 ZA ZA200506504A patent/ZA200506504B/en unknown
- 2005-08-22 IL IL170414A patent/IL170414A/en active IP Right Grant
- 2005-09-26 NO NO20054440A patent/NO20054440L/no not_active Application Discontinuation
2006
- 2006-07-19 HK HK06108097.9A patent/HK1085677A1/xx not_active IP Right Cessation
2014
- 2014-12-15 US US14/570,244 patent/US9512215B2/en not_active Expired - Lifetime
2016
- 2016-09-30 US US15/283,001 patent/US20170020960A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MXPA05009135A (es)	2005-10-20
CA2515539A1 (en)	2004-09-10
US20070053906A1 (en)	2007-03-08
ATE394123T1 (de)	2008-05-15
US20150098950A1 (en)	2015-04-09
EP1603596A1 (en)	2005-12-14
AU2004216483A1 (en)	2004-09-10
HK1085677A1 (en)	2006-09-01
EP1603596B1 (en)	2008-05-07
HRP20050706A2 (en)	2005-12-31
RS51041B (sr)	2010-10-31
AR043418A1 (es)	2005-07-27
ZA200506504B (en)	2006-12-27
UA82503C2 (uk)	2008-04-25
EA200501230A1 (ru)	2006-04-28
PL378290A1 (pl)	2006-03-20
IL170414A (en)	2009-11-18
KR20050105486A (ko)	2005-11-04
PL213501B1 (pl)	2013-03-29
WO2004075918A1 (en)	2004-09-10
JP2006519210A (ja)	2006-08-24
DE602004013557D1 (de)	2008-06-19
CN1774266A (zh)	2006-05-17
CN100563712C (zh)	2009-12-02
JP4980048B2 (ja)	2012-07-18
EA009079B1 (ru)	2007-10-26
ES2304602T3 (es)	2008-10-16
BRPI0407649A (pt)	2006-02-21
US9512215B2 (en)	2016-12-06
RS20050662A (en)	2007-11-15
US8937045B2 (en)	2015-01-20
US20170020960A1 (en)	2017-01-26

Publication	Publication Date	Title
ATE382057T1 (de)	2008-01-15	Stabile formulierung von modifiziertem glp-1
NO20054440L (no)	2005-09-26	Flytende formuleringer av tumornekrosefaktorbindende proteiner
ZA200309460B (en)	2004-09-01	Novel Benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl trasferase proteins.
SV2006002174A (es)	2006-03-06	Composicion de anticuerpo her2
NO20040564L (no)	2004-05-10	Karboksylsyrederivatforbindelser og legemidler omfattende disse forbindelser som den aktive bestanddel
NO331093B1 (no)	2011-10-03	Somatostatinanaloger, fremgangsmåte for fremstilling, farmasøytisk sammensetning og anvendelse derav.
NO20065860L (no)	2006-12-19	Stabiliserte flytende interferonformuleringer
BR0115810B1 (pt)	2011-10-18	composições cosméticas, dermatológicas e farmacêuticas isentas de tensoativos.
NO20043702L (no)	2004-12-03	8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
NO20040356L (no)	2004-03-19	Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
IS2485B (is)	2008-12-15	Fenýlsúlfónýl-1,3-díhýdró-2H-indól-2-ón afleiður,framleiðsla þeirra og notkun í meðferðarskyni
NO20032438D0 (no)	2003-05-28	Orto- og metasubstituerte bis-arylforbindelser, deres fremstilling og anvendelse samt farmasöytiske preparater inneholdende forbindelsene
DK1498411T3 (da)	2013-04-15	Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
DE60209929D1 (de)	2006-05-11	Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
IL161582A0 (en)	2004-09-27	Use of oxindole hydrazide derivatives for the preparation of pharmaceutical compositions, certain such new derivatives and their preparation
BR0314797A (pt)	2005-07-26	Derivados da pirimidineamida e o uso dos mesmos
DE50005529D1 (de)	2004-04-08	Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60322720D1 (de)	2008-09-18	Feste formulierungen enthaltend eine indolinon verbindung
WO2005018605A3 (en)	2005-11-03	Novel formulation of ropinirole
NO20055838L (no)	2006-02-13	Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav
NO20042563L (no)	2004-06-18	Preparatsammensetning som inneholder syreustabile fysiologisk aktive forbindelser og fremgangsmater til fremstilling derav
ITRM20030363A1 (it)	2005-01-25	Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
IS7815A (is)	2005-04-20	3-Fenýl setið pýridóindólón, framleiðsla og meðferðarleg notkun þess.
NO20022022L (no)	2002-04-29	N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
ATE404602T1 (de)	2008-08-15	Wässrige polyurethanzubereitungen

Legal Events

Date	Code	Title	Description
2013-09-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application